Back to search results

Blood Sampling for Sickle Cell Disease Research

This observational study is collecting blood samples from adults (18-100 years old) with sickle cell trait, sickle cell disease, or healthy volunteers. The goal is to find new treatments for sickle cell disease by testing many compounds, including existing FDA-approved drugs, for their ability to stop red blood cells from sickling. Researchers hope to discover a drug that can effectively treat sickle cell disease, as current treatments like hydroxyurea are only partly effective. You would be screened with a medical history to see if you can join.

Study design
This is an observational study planning to enroll 250 participants. It is not testing a specific drug or intervention.
What's involved
You would donate small blood samples periodically for ongoing tests. You would also have your hemoglobinopathies verified.
Compensation
Not stated in the trial record.
Follow-up
Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT00542230

Blood Sampling for Research Related to Sickle Cell Disease

Recruiting
Not specifiedAges 18+Observational
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
~250 participants
Updated 2026-09-16 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To screen large compound libraries for anti-sickling activity, particularly compounds that are already FDA-approved drugs, with the goal of discovering a drug for treating sickle cell disease.
Measured over daily

Conditions

Sickle Cell Trait
Sickle Cell Disease
Sickle Cell Anemia

Explore related trials

Sickle Cell DiseaseSickle Cell TraitHemoglobin S

NCT00542230

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • National Institutes of Health Clinical Center

    Bethesda, Marylandno site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • William A Eaton, M.D. · PRINCIPAL_INVESTIGATOR · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Who to contact

William A Eaton, M.D.
[email protected]
(301) 496-6030
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients with sickle cell trait
Patients with known hemoglobinopathies involving one or two genes for sickle hemoglobin
Healthy volunteers for control experiments
Age range: adults greater than or equal to 18 years of age

Exclusion

Subjects who are unable to comprehend the investigational nature of the laboratory research are ineligible to enroll in this protocol.
As a safety precaution in handling the blood samples, patients with HIV, Hepatitis B or Hepatitis C will be excluded from the study. HIV, Hepatitis B or Hepatitits C testing will not be done under this study. Participants must be co-enrolled under another NIH protocol where the screening evaluation has been performed.

What this trial measures

  • To screen large compound libraries for anti-sickling activity, particularly compounds that are already FDA-approved drugs, with the goal of discovering a drug for treating sickle cell disease.daily

    To identify by high sensitivity in vitro screening methods additional compounds that inhibit sickling